SuperworthCrescent Biopharma shares outstanding CBIO
Diluted shares outstanding, averaged over each quarter, from 2013.
- Latest quarter, to Dec 31, 2024
- 644.8K
- On a year earlier
- +0.2%
- more shares
Crescent Biopharma had 644.8K diluted shares outstanding on average in Q4 FY24, the quarter to Dec 31, 2024.
That is about the same as a year earlier.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2024 | 644.8K | +0% |
| FY2023 | 643.8K | +22% |
| FY2022 | 529.6K | +2% |
| FY2021 | 520.1K | +8% |
| FY2020 | 479.8K | +11% |
| FY2019 | 433.7K | +1% |
| FY2018 | 431.2K | +168% |
| FY2017 | 161.2K | −30% |
| FY2016 | 231K | +21% |
| FY2015 | 190.4K | +1% |
| FY2014 | 188.7K | +1031% |
| FY2013 | 16.7K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q4 FY24 | 644.8K | +0% | |
| Q3 FY24 | 644.8K | +0% | |
| Q2 FY24 | 644.8K | +0% | |
| Q1 FY24 | 645.2K | +7% | |
| Q4 FY23 | 643.8K | +22% | |
| Q3 FY23 | 643.5K | +23% | |
| Q2 FY23 | 642.8K | +23% | |
| Q1 FY23 | 603.5K | +15% | |
| Q4 FY22 | 529.6K | +2% | |
| Q3 FY22 | 524.2K | +2% | |
| Q2 FY22 | 524.1K | +2% | |
| Q1 FY22 | 523.3K | +3% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Crescent Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.